Jazz Pharmaceuticals (JAZZ) is one of the 7 most undervalued pot stocks to buy, presenting at the Goldman Sachs Healthcare Conference. The company highlights strong growth in its neuroscience segment with products like Xywav and Epidiolex showing promising results in the first quarter of 2025.

Jazz Pharmaceuticals is expanding its oncology portfolio and pipeline, focusing on key initiatives like Zanidatamab, Zepzelca, Subzelca, and Dordavapril. The company emphasizes upcoming product launches and regulatory decisions to drive future growth, including the orexin program and prasinezumab in Europe.

Jazz Pharmaceuticals has expanded into the cannabis sector through the acquisition of GW Pharmaceuticals, developing FDA-approved drugs containing purified cannabis-based substances like CBD. While JAZZ shows investment potential, other AI stocks may offer greater upside potential and less downside risk, particularly in the current market climate.

Investors seeking opportunities in the AI sector may find greater potential in other stocks compared to Jazz Pharmaceuticals. The company’s expansion into the cannabis sector and strategic growth initiatives present opportunities for growth, but other AI stocks may offer more substantial benefits in the current market environment.

Read more at Yahoo Finance: Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference